IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

2 FW 1648

In re Patent Application of

MAERTENS et al.

Atty. Ref.: 2

2551-68

Serial No.

09/995,791

Group:

1648

Filed:

November 29, 2001

Examiner:

MOSHER, Mary

For:

PURIFIED HEPATITIS C VIRUS ENVELOPE PROTEINS

FOR DIAGNOSTIC AND THERAPEUTIC USE

* * * * * * * *

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 August 25, 2004

Sir:

INFORMATION DISCLOSURE STATEMENT

	1.	PTO-1449 Pursuant to 37 CFR 1.97(b) [within 3 months of filing or prior to 1st Office Action on	the merits] <i>N/C</i>
	2.(a)	Statement Pursuant to 37 CFR 1.97(c) [before Final Office Action or Allowance (requires Rule Statement or Rule 17(p) fee)]	97(e) N/C
\boxtimes	2 .(b)	Fee Payment Pursuant to 37 CFR 1.97(c) [before Final Office Action or Allowance (requires Rule Statement or Rule 17(p) fee)]	97(e) <i>\$180.00</i>
	3.	Pursuant to 37 CFR 1.97(d) [after Final Office Action or Allowance (requires Rule 97)	7(e)

Statement and Rule 17(p) fee), but before final fee payment]

08/26/2004 EABUBAK1 00000083 09995791

01 FC:1806

180.00 OP

\$180.00

MAERTENS et al. Serial No. 09/995,791

The following are submitted in the above-identified application in compliance with 37 C.F.R. §§ 1.97 and 1.98: X A list of documents on Form PTO-1449 together with copies of each 4. identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith. This paper is submitted in accordance with: 5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action] \boxtimes 6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and a) The required Statement made in item 8 below; or \boxtimes The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this b) Information Disclosure Statement is authorized in item 9 below. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) 7. Statement and Rule 17(p) fee), but before final fee payment]; and The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; a) and П b) The required Statement is stated in item 8 below. 8. Statement under 37 CFR 1.97(e) П a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

MAEF	RTEN	VS et	al.	
Serial	No.	09/99	95,79	1

9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted, NIXON & VANDERHYE P.C.

By:

| Sadoft | Sado

Reg. No. 36,663

1100 North Glebe Road, 8th Floor

Arlington, VA 22201-4714 Telephone: (703) 816-4000 Facsimile: (703) 816-4100

			OIPE						
Sheet	1. of 1		e mon						
INFORM	MATION DISCLOS	JRE ATTY.	DOCKETNO. Q AUB 2	SERIAL NO.					
	CITATION	2551	V)	09/995,791					
		APPLIC	RADEMA						
(Use	several sheets if necessary)	MAEI FILING	RTENS et al.	GROUP					
		Nove	mber 29, 2001	1648					
		U.S	S. PATENT DOCUMENTS						
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING IF APPRO			
						L			
		FOR	EIGN PATENT DOCUMENTS			TRANC	LATION		
			COUNTRY	CLASS	SUBCLASS	YES	LATION NO		
	DOCUMENT	DATE	COUNTRY	CLASS	T		г		
	WO 96/13590	05/1996	WIPO						
	AU 199957127		Australia						
	WO 96/04385	02/1996	WIPO						
						<u> </u>	<u> </u>		
						 			
					-	-			
	OTUED BOOK	AFAITO /im	aluding Author Title Date I	Portinent no	ance otc	1	<u> </u>		
	OTHER DOCU	VIEN IS (In	cluding Author, Title, Date, F	0 pp 2020-	2025	<u></u>			
	Song et al, Journal of Virology, Vol. 74, No. 6, March 2000, pp 2920-2925								
	Lopez-Diaz de Cerio et al, International Immunology, Vol. 11, No. 12, 1999, pp 2025-2033 Saito et al, Gastroenterology, Vol. 112, 1997, pp 1321-1330 Lee et al, Journal of Virology, Vol. 73, No. 1, January 1999, pp 11-18								
				o, pp 11-10					
	Esumi et al, Arch. Virol, Vol. 144, 1999, pp 973-980								
	Heile et al, Journal of Virology, Vol. 74, No. 15, August 2000, pp 6885-6892 Seong et al, Virus Research, Vol. 55, 1998, pp 177-185								
	Howard et al, Developments in Biological Standardization, Vol. 92, 1998, pp 157-162								
		· <u>-</u> -							

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

*Examiner

Date Considered

Form PTO-FB-A820 (Also PTO-1449)